Providing a diverse range of perspectives from bullish to bearish, 12 analysts have published ratings on Tenet Healthcare THC in the last three months.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 8 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 3 | 0 | 0 | 0 |
| 2M Ago | 1 | 3 | 0 | 0 | 0 |
| 3M Ago | 2 | 2 | 0 | 0 | 0 |
Analysts have recently evaluated Tenet Healthcare and provided 12-month price targets. The average target is $109.75, accompanied by a high estimate of $126.00 and a low estimate of $100.00. Marking an increase of 13.14%, the current average surpasses the previous average price target of $97.00.
Analyzing Analyst Ratings: A Detailed Breakdown
The standing of Tenet Healthcare among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Pito Chickering | Deutsche Bank | Raises | Buy | $126.00 | $100.00 |
| Sarah James | Cantor Fitzgerald | Maintains | Overweight | $104.00 | - |
| Stephen Baxter | Wells Fargo | Raises | Overweight | $115.00 | $105.00 |
| Justin Lake | Wolfe Research | Announces | Outperform | $122.00 | - |
| Ann Hynes | Mizuho | Raises | Buy | $110.00 | $100.00 |
| Andrew Mok | Barclays | Announces | Overweight | $113.00 | - |
| Sarah James | Cantor Fitzgerald | Maintains | Overweight | $104.00 | - |
| Stephen Baxter | Wells Fargo | Raises | Overweight | $105.00 | $98.00 |
| David Macdonald | Truist Securities | Raises | Buy | $105.00 | $92.00 |
| Ben Hendrix | RBC Capital | Raises | Outperform | $109.00 | $97.00 |
| Ann Hynes | Mizuho | Raises | Buy | $100.00 | $90.00 |
| Sarah James | Cantor Fitzgerald | Raises | Overweight | $104.00 | $94.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Tenet Healthcare. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Tenet Healthcare compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Tenet Healthcare's stock. This comparison reveals trends in analysts' expectations over time.
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Tenet Healthcare's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Tenet Healthcare analyst ratings.
All You Need to Know About Tenet Healthcare
Tenet Healthcare is a Dallas-based healthcare services organization. It operates a collection of hospitals (about 60 as of December 2023) and over 450 ambulatory surgery centers and other outpatient facilities across the U.S., primarily in the South. Through its Conifer segment, Tenet also provides revenue cycle management solutions.
Unraveling the Financial Story of Tenet Healthcare
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Over the 3 months period, Tenet Healthcare showcased positive performance, achieving a revenue growth rate of 7.8% as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 4.54%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Tenet Healthcare's ROE excels beyond industry benchmarks, reaching 15.89%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Tenet Healthcare's ROA excels beyond industry benchmarks, reaching 0.87%. This signifies efficient management of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 9.33, Tenet Healthcare faces challenges in effectively managing its debt levels, indicating potential financial strain.
Analyst Ratings: What Are They?
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
